GEN Exclusives

More »

GEN News Highlights

More »
Feb 10, 2011

Cephalon Pays Alba $7M for Option to Purchase Clinical-Phase Celiac Disease Drug

  • Cephalon is paying Alba Therapeutics $7 million to secure an option for the future purchase of its clinical-stage larazotide acetate candidate for the treatment of celiac disease. The oral peptide-based tight junction modulator is progressing toward Phase IIb development, and Cephalon has the right to exercise its purchase option during a specified time period after full Phase IIb trial results have been reported. If Cephalon does decide to take on the larazotide assets, the firm will pay Alba $15 million, and potentially additional regulatory and sales milestones.

    Alba has been working on larazotide R&D for the last six years, and the peptide has already been tested in some 450 celiac disease patients. Cephalon says results to date have been encouraging. “Alba will now initiate a Phase IIb trial utilizing a more disease-specific primary endpoint. “If successful, larazotide acetate will add to our pipeline in immunology and has the potential to be the first pharmacologic therapy available to treat patients who endure this often serious condition.”

     


Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Alzheimer's Therapies

Do you think an effective treatment for Alzheimer’s will be found within the next 10–15 years?